Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis

References

• SmolenJSLandewéRBijlsmaJEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnn Rheum Dis201776696097728264816
   PubMed Web of Science ®Google Scholar
• PincusTBergmanMJYaziciYLimitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?Clin Exp Rheumatol2015335 Suppl 93S82S93
   Web of Science ®Google Scholar
• PuigLMethotrexate: new therapeutic approachesActas Dermosifiliogr2014105658358923434058
   PubMedGoogle Scholar
• ZweegersJOteroMEvan den ReekJMEffectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: a systematic reviewActa Derm Venereol201696445345826537336
   PubMed Web of Science ®Google Scholar
• LimaASousaHMonteiroJAzevedoRMedeirosRSeabraVGenetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkersPharmacogenomics201415121611163525340735
   PubMed Web of Science ®Google Scholar
• MoyaPCorominasHSalazarJDíaz-TornéCA step forward in methotrexate pharmacogeneticsReumatol Clin201713530528110875
   PubMed Web of Science ®Google Scholar
• SharmaPScottDGOptimizing methotrexate treatment in rheumatoid arthritis: the case for subcutaneous methotrexate prior to biologicsDrugs201575171953195626474779
   PubMed Web of Science ®Google Scholar
• BelloAEPerkinsELJayREfthimiouPRecommendations for optimizing methotrexate treatment for patients with rheumatoid arthritisOpen Access Rheumatol20179677928435338
   PubMed Web of Science ®Google Scholar
• YadlapatiSEfthimiouPInadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?Rheumatol Int201636562763326936262
   PubMed Web of Science ®Google Scholar
• JundtJWBrowneBAFioccoGPSteeleADMockDA comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosingJ Rheumatol19932011184518498308768
   PubMed Web of Science ®Google Scholar
• BrooksPJSpruillWJParishRCBirchmoreDAPharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritisArthritis Rheum199033191942302272
   PubMed Web of Science ®Google Scholar
• HoekstraMHaagsmaCNeefCProostJKnuifAvan de LaarMBioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritisJ Rheumatol200431464564815088287
   PubMed Web of Science ®Google Scholar
• SchiffMHJaffeJSFreundlichBHead-to-head, randomized, crossover study of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses $15 mg may be overcome with subcutaneous administrationAnn Rheum Dis20147381549155124728329
   PubMed Web of Science ®Google Scholar
• TukováJChládekJNemcováDChládkováJDolezalováPMethotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritisClin Exp Rheumatol20092761047105320149329
   PubMed Web of Science ®Google Scholar
• PichlmeierUHeuerKUSubcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexateClin Exp Rheumatol201432456357124983446
   PubMed Web of Science ®Google Scholar
• KurnikDLoebsteinRFishbeinEBioavailability of oral vs subcutaneous low-dose methotrexate in patients with Crohn’s diseaseAliment Pharmacol Ther2003181576312848626
   PubMed Web of Science ®Google Scholar
• WilsonAPatelVChandeNPharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s diseaseAliment Pharmacol Ther201337334034523190184
   PubMed Web of Science ®Google Scholar
• LiDYangZKangPXieXSubcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysisSemin Arthritis Rheum201645665666226686022
   PubMed Web of Science ®Google Scholar
• SchiffMHSadowskiPOral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritisRheumatol Int201737221321828012023
   PubMed Web of Science ®Google Scholar
• QuistSRQuistJBirkenmaierJStauchTGollnickHPPharmacokinetic profile of methotrexate in psoriatic skin via the oral or subcutaneous route using dermal microdialysis showing higher methotrexate bioavailability in psoriasis plaques than in non-lesional skinJ Eur Acad Dermatol Venereol20163091537154327005005
   PubMed Web of Science ®Google Scholar
• CronsteinBNLow-dose methotrexate: a mainstay in the treatment of rheumatoid arthritisPharmacol Rev200557216317215914465
   PubMed Web of Science ®Google Scholar
• MohamedHJSorichMJKowalskiSMThe role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies–a systematic reviewEur J Clin Pharmacol201571441142325687918
   PubMed Web of Science ®Google Scholar
• DervieuxTZablockiRKremerJRed blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritisRheumatology (Oxford)201049122337234520713496
   PubMed Web of Science ®Google Scholar
• StampLKBarclayMLO’DonnellJLEffects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritisJ Rheumatol201138122540254721965639
   PubMed Web of Science ®Google Scholar
• BeckerMLvan HaandelLGaedigkRAnalysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrationsArthritis Rheum20106261803181220191581
   PubMed Web of Science ®Google Scholar
• O’ConnorAThorneCKangHTinDPopeJEThe rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational studyBMC Musculoskelet Disord201617136427558249
   PubMed Web of Science ®Google Scholar
• BraunJKästnerPFlaxenbergPMC-MT.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous vs oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trialArthritis Rheum2008581738118163521
   PubMed Web of Science ®Google Scholar
• IslamMSHaqSAIslamMNComparative efficacy of subcutaneous vs oral methotrexate in active rheumatoid arthritisMymensingh Med J201322348348823982537
   PubMedGoogle Scholar
• HazlewoodGSThorneJCPopeJECATCH InvestigatorsThe comparative effectiveness of oral vs subcutaneous methotrexate for the treatment of early rheumatoid arthritisAnn Rheum Dis20167561003100825979945
   PubMed Web of Science ®Google Scholar
• KleinAKaulIFoeldvariIGanserGUrbanAHorneffGEfficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate RegistryArthritis Care Res (Hoboken)20126491349135622649024
   PubMed Web of Science ®Google Scholar
• FráňováJFingerhutováŠKobrováKMethotrexate efficacy, but not its intolerance, is associated with the dose and route of administrationPediatr Rheumatol Online J20161413627301536
   PubMed Web of Science ®Google Scholar
• RozinASchapiraDBalbir-GurmanARelapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexateAnn Rheum Dis200261875675712117691
   PubMed Web of Science ®Google Scholar
• ScottDGClaydonPEllisCRetrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR studyScand J Rheumatol201443647047624898259
   PubMed Web of Science ®Google Scholar
• BakkerMFJacobsJWWelsingPMUtrecht Arthritis Cohort Study GroupAre switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA studyAnn Rheum Dis201069101849185220511610
   PubMed Web of Science ®Google Scholar
• BormanPDemirGKaygısızFOkumuşMLETTER TO THE EDITOR Subcutaneous (SC) methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effectsOpen Rheumatol J20148181925232363
   PubMedGoogle Scholar
• HameedBJonesHSubcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritisInt J Rheum Dis2010134e83e8421199461
   PubMed Web of Science ®Google Scholar
• MainmanHMcClarenEHeycockCSaravananVHamiltonJKellyCWhen should we use parenteral methotrexate?Clin Rheumatol201029101093109820544244
   PubMed Web of Science ®Google Scholar
• BrancoJCBarcelosAde AraújoFPUtilization of subcutaneous methotrexate in rheumatoid arthritis patients after failure or intolerance to oral methotrexate: a multicenter cohort studyAdv Ther2016331465726724937
   PubMed Web of Science ®Google Scholar
• AlsufyaniKOrtiz-AlvarezOCabralDATuckerLBPettyREMallesonPNThe role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexateJ Rheumatol200431117918214705239
   PubMed Web of Science ®Google Scholar
• ŻuberZTurowska-HeydelDSobczykMMethotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritisReumatologia2016541192327407272
   PubMedGoogle Scholar
• CurtisJRXieFMackeyDPatient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritisBMC Musculoskelet Disord201617140527669978
   PubMed Web of Science ®Google Scholar
• PatilPParkerRARawcliffeCMethotrexate-induced nausea and vomiting in adolescent and young adult patientsClin Rheumatol201433340340724108504
   PubMed Web of Science ®Google Scholar
• van DijkhuizenEHPouwJNScheuernAMethotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational studyClin Exp Rheumatol2016341148154
   Web of Science ®Google Scholar
• KromannCBLage-HansenPRKoefoedMJemecGBDoes switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?J Dermatolog Treat201526218819024852821
   PubMed Web of Science ®Google Scholar
• Rutkowska-SakLRell-BakalarskaMLisowskaBOral vs subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effectsReumatologia200947207211
   Google Scholar
• BulatovićMHeijstekMWVerkaaikMHigh prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity scoreArthritis Rheum20116372007201321437879
   PubMed Web of Science ®Google Scholar
• MulliganKWedderburnLRNewmanSThe experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young peoplePediatr Rheumatol Online J2015135826653415
   PubMed Web of Science ®Google Scholar
• CurtisJRZhangJXieFBeukelmanTUse of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United StatesArthritis Care Res (Hoboken)2014661604161124942466
   PubMed Web of Science ®Google Scholar
• FitzpatrickRScottDGKearyICost-minimisation analysis of subcutaneous methotrexate vs biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexateClin Rheumatol2013321605161223835658
   PubMed Web of Science ®Google Scholar
• LeeJPelkeyRGubitosaJHenrickMFGanzMLComparing healthcare costs associated with oral and subcutaneous methotrexate or biologic therapy for rheumatoid arthritis in the United StatesAm Health Drug Benefits2017101424928465768
   PubMed Web of Science ®Google Scholar
• MontaudiéHSbidianEPaulCMethotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicityJ Eur Acad Dermatol Venereol201125Suppl 21218
   PubMed Web of Science ®Google Scholar
• DupuisECBholeVMDutzJPDiffering patterns of methotrexate use for psoriatic disease among dermatologists and rheumatologistsBr J Dermatol2012167244845022309601
   PubMed Web of Science ®Google Scholar
• ZargariOHejaziSShahidi-DadrasMConsiderable variation among Iranian dermatologists in the dosing and monitoring of methotrexate for treating psoriasisInt J Dermatol201453338538924134730
   PubMed Web of Science ®Google Scholar
• WarrenRBMrowietzUvon KiedrowskiRAn intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomized, double-blind, placebo-controlled, phase 3 trialLancet20173891006852853728012564
   PubMed Web of Science ®Google Scholar
• YesudianPDLemanJBalasubramaniamPEffectiveness of subcutaneous methotrexate in chronic plaque psoriasisJ Drugs Dermatol201615334534926954320
   PubMedGoogle Scholar
• VidalDSallerasMRomaníJAdherence of self-administered subcutaneous methotrexate in patients with chronic plaque-type psoriasisJ Eur Acad Dermatol Venereol20163011e131e13226446358
   PubMed Web of Science ®Google Scholar
• BianchiGCaporaliRTodoertiMMattanaPMethotrexate and rheumatoid arthritis: Current evidence regarding subcutaneous vs oral routes of administrationAdv Ther201633336937826846283
   PubMed Web of Science ®Google Scholar
• TodoertiMMaglioneWBerneroESystematic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritisReumatismo201365520721824399184
   PubMedGoogle Scholar